Nizar J. Bahlis, MD
Selinexor combined with weekly bortezomib (Velcade) and low-dose dexamethasone (Vd) produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma (RRMM).
Based on tolerability and efficacy, the recommended phase II dose of selinexor plus Vd is selinexor at 100 mg, bortezomib at 1.3 mg/m2, and dexamethasone at 40 mg, all weekly. These doses represent 40% less bortezomib and 25% less dexamethasone compared with the standard approved twice weekly schedule of Vd, Bahlis said.
Bahlis NJ, Sutherland H, White DJ, et al. Selinexor in combination with weekly low dose bortezomib and dexamethasone (SVd) induces a high response rate with durable responses in patients with refractory multiple myeloma (MM). Presented at: American Society of Hematology 59th Annual meeting; December 9-12, 2017; Atlanta, GA. Abstract 3135.
... to read the full story